ORIC shareholder plans sale of 7,000 shares

ORIC Pharmaceuticals filed a notice that a shareholder plans to sell 7,000 shares of common stock through J.P.

Rhea-AI Filing Summary

ORIC Pharmaceuticals filed a notice that a shareholder plans to sell 7,000 shares of common stock through J.P. Morgan Securities LLC on Nasdaq, with an aggregate market value of $84,000. The filing lists 97,389,279 shares of common stock outstanding. The shares to be sold were acquired on 08/25/2016 by exercising stock options for cash on that same date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does ORIC's Form 144 filing disclose?

It discloses that a shareholder plans to sell 7,000 shares of ORIC common stock through J.P. Morgan Securities LLC on the Nasdaq exchange, with an aggregate market value of $84,000.

How many ORIC shares are planned to be sold under this Form 144?

The notice covers a planned sale of 7,000 shares of ORIC common stock.

What is the aggregate market value of the ORIC shares to be sold?

The aggregate market value of the 7,000 ORIC common shares to be sold is listed as $84,000.

When were the ORIC shares to be sold originally acquired?

The 7,000 shares were acquired on 08/25/2016 through a stock option exercise paid in cash.

How many ORIC shares are shown as outstanding in this filing?

The filing lists 97,389,279 shares of ORIC common stock as outstanding.

On which exchange will the ORIC shares be sold and through which broker?

The planned sale is through J.P. Morgan Securities LLC on the Nasdaq exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/16/2026 - 04:43 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001584759
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Oric Pharmaceuticals, Inc.
SEC File Number	001-39269
Address of Issuer	240 E. Grand Ave 2nd Floor San Francisco CALIFORNIA 94080
Phone	6503885600
Name of Person for Whose Account the Securities are To Be Sold	Richard A, Heyman
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	J.P. Morgan Securities LLC 270 Park Avenue 10th Floor New York NY 10017	7000	84000	97389279	01/16/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/25/2016	Stock Option Exercise	Issuer			7000	08/25/2016	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	01/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Richard A. Heyman.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)